← Back to Search

Monoclonal Antibodies

TEV-48574 for Asthma

Phase 2
Waitlist Available
Research Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization (week 0) until week 24
Awards & highlights

Study Summary

A Study to Test if TEV-48574 is Effective in Relieving Asthma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization (week 0) until week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization (week 0) until week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period
Secondary outcome measures
Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16
Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16
Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16
+9 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TEV-48574Experimental Treatment1 Intervention
Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.

Find a Location

Who is running the clinical trial?

Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
251 Previous Clinical Trials
3,485,313 Total Patients Enrolled
63 Trials studying Asthma
2,616,146 Patients Enrolled for Asthma
Teva Medical Expert, MDStudy DirectorTeva Branded Pharmaceutical Products R&D, Inc.
93 Previous Clinical Trials
38,716 Total Patients Enrolled
22 Trials studying Asthma
12,575 Patients Enrolled for Asthma
~14 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top